Your Health, We Care
Release date: 2026-04-17 15:34:57 Recommended: 13
In terms of treatment response rate, Selinexor also demonstrates advantages. Among adult patients receiving a Selinexor-containing regimen, up to 76% achieved at least a partial treatment response, compared to 62% in the control group. This means that more than three out of every four patients treated with Selinexor benefit from the therapy. Even more encouragingly, the responses induced by Selinexor last longer: among patients who responded to the Selinexor-containing regimen, half had a response duration of at least 20 months; in contrast, the corresponding figure for the control group was only 13 months. Furthermore, among the responder population, half observed a treatment response within one and a half months after starting therapy, indicating a reasonably rapid onset of action.
A pivotal clinical trial enrolled 402 adult patients with relapsed multiple myeloma who had received 1 to 3 prior lines of therapy. The results showed that patients receiving a Selinexor-containing regimen (in combination with bortezomib and dexamethasone, referred to as the XVd regimen) had a median progression-free survival (PFS) of 13.9 months, compared to only 9.5 months for patients receiving a regimen without Selinexor. This means that Selinexor helped patients gain an additional 4.4 months of disease stability. It is important to emphasize that this is a median value — at the median follow-up time of 15.1 months, half of the patients treated with Selinexor had not experienced disease progression, and their PFS exceeded 13.9 months. This difference is statistically significant, providing a powerful new option for patients with relapsed multiple myeloma.
The Selinexor clinical trials enrolled a wide variety of patients with multiple myeloma, fully demonstrating its broad applicability. The trial population included elderly patients over 65 years of age, patients with reduced kidney function, and patients with high-risk genetic mutations (such as del(17p)). These special populations often have difficulty achieving ideal treatment responses in clinical trials, yet Selinexor still showed good efficacy in these individuals. Additionally, patients receiving the Selinexor-containing regimen required 37% fewer outpatient visits for treatment administration during the first six months compared to the control group. For multiple myeloma patients who frequently travel to and from the hospital, this means less time on the road and a higher quality of life. If you are experiencing your first relapse, Selinexor may be a treatment option worth discussing seriously with your doctor.
